Spring til hovednavigation Spring til søgning Spring til hovedindhold

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries

  • Benedicte Delcoigne
  • , Lotta Ljung
  • , Sella A Provan
  • , Bente Glintborg
  • , Merete Lund Hetland
  • , Kathrine Lederballe Grøn
  • , Ritva Peltomaa
  • , Heikki Relas
  • , Carl Turesson
  • , Bjorn Gudbjornsson
  • , Brigitte Michelsen
  • , Johan Askling
16 Citationer (Scopus)

Abstract

OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical practice and to anchor these results with a general population comparator.

METHODS: Observational cohort study, with patients from Denmark, Finland, Norway and Sweden starting a bDMARD during 2008-2017. Time to first ACS was identified through register linkages. We calculated the 1-year, 2-year and 5-year incidence rates (IR) (on drug and ever since treatment start) and used Cox regression (HRs) to compare ACS incidences across treatments taking ACS risk factors into account. Analyses were further performed separately in subgroups defined by age, number of previous bDMARDs and history of cardiovascular disease. We also compared ACS incidences to an individually matched general population cohort.

RESULTS: 24 083 patients (75% women, mean age 56 years) contributing 40 850 treatment courses were included. During the maximum (5 years) follow-up (141 257 person-years (pyrs)), 780 ACS events occurred (crude IR 5.5 per 1000 pyrs). Overall, the incidence of ACS in RA was 80% higher than that in the general population. For all bDMARDs and follow-up definitions, HRs were close to 1 (etanercept as reference) with the exception of the 5-year risk window, where signals for abatacept, infliximab and rituximab were noted.

CONCLUSION: The rate of ACS among patients with RA initiating bDMARDs remains elevated compared with the general population. As used in routine care, the short-term, intermediate-term and longer-term risks of ACS vary little across individual bDMARDs.

OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
Vol/bind81
Udgave nummer6
Sider (fra-til)789-797
Antal sider9
ISSN0003-4967
DOI
StatusUdgivet - jun. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries'. Sammen danner de et unikt fingeraftryk.

Citationsformater